---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011583"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:42:47.152961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Collegium Q2 revenue up 7% to $145.3M; adjusted EPS $1.62; Ironshore acquisition on track

## Summary
- Net revenue $145.3M (+7% YoY); Belbuca record $52.2M (+21% YoY); GAAP net income $19.6M (+51% YoY).
- Non-GAAP adjusted net income $64.0M, adjusted EPS $1.62; Adjusted EBITDA $96.0M (+12% YoY).
- Acquiring Ironshore Therapeutics for $525M cash + up to $25M milestone; expected close Q3'24; funded by new $646M term loan.
- Reaffirmed FY2024 guidance: Product Revenue $580-595M, Adjusted EBITDA $380-395M.
- Pediatric exclusivity for Nucynta franchise extended to Jan 2027 (Nucynta) and Dec 2025 (Nucynta ER).

## SEC filing metadata
- accession: 0001558370-24-011583
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837024011583/0001558370-24-011583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837024011583/coll-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011583
- JSON: https://secwatch.observer/filing/0001558370-24-011583.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.